Edwards Lifesciences Corporation EW
86.29
0.56
0.65%
as of 25 Sep
- Market cap
- $49.4B
- P/E
- 49.6×
Follow EW
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
13.81% | 10.52% | 10.68% | 9.42% | |
| 10.42% | 8.03% | 8.32% | 7.35% | ||
ROIC |
12.80% | 11.78% | 11.60% | 12.81% | |
Return on Tangible Assets |
21.00% | 15.93% | 16.50% | 14.05% | |
Average Days of Receivables |
55.38 | 54.87 | 56.34 | 53.56 | |
Free Cash Flow per Share |
1.38 | 2.28 | 1.88 | 2.49 | |
Free Cash Flow |
804.20 | 1,335.00 | 1,089.50 | 1,433.60 | |
Capital Expenditures |
(212.60) | (260.20) | (269.10) | (286.70) | |
Piotroski F-Score |
4.00 | 4.00 | 4.00 | 4.00 | |
| Other line items | |||||
Cash ROIC |
6.94% | 10.52% | 9.31% | 11.04% | |
Accounts Receivable Turnover |
6.90 | 7.40 | 7.31 | 7.01 | |
Accounts Payable Turnover |
7.60 | 6.28 | 7.89 | 7.75 | |
Inventory Turnover |
1.14 | 1.21 | 1.25 | 1.27 | |
Average Days of Payables |
46.93 | 62.24 | 47.38 | 53.24 | |
Days of Inventory on Hand |
324.47 | 308.10 | 292.74 | 286.09 | |
Tax Rate |
(0.15) | (0.17) | (0.17) | (0.31) | |
Research and Development Expense of Revenue |
18.40% | 17.79% | 17.26% | 16.75% | |
Selling, General and Administrative Expense of Revenue |
33.55% | 34.37% | 33.98% | 33.80% | |
Share Based Compensation of Revenue |
2.56% | 2.61% | 2.59% | 2.58% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.74 | 1.49 | 1.24 | 1.71 | |
Depreciation/Fixed assets |
0.09 | 0.09 | 0.09 | 0.09 | |
Capex/Depreciation |
(1.36) | (1.66) | (1.67) | (1.73) | |
Revenue per Share |
10.06 | 10.38 | 10.88 | 11.30 | |
Operating CF per Share |
1.74 | 2.73 | 2.35 | 2.98 | |
Capex per Share |
(0.36) | (0.44) | (0.46) | (0.50) | |
Capex to Sales |
0.04 | 0.04 | 0.04 | 0.04 | |
Net Profit Margin |
23.25% | 17.69% | 17.39% | 15.43% |
Columns are period end dates